- Combining Hsp90 inhibition with ganetespib and anti-angiogenic therapy with Ziv-Aflibercept, a soluble fusion protein with high binding affinity for VEGF-A, VEGF-B, and PIGF, presents a rational novel strategy for improving upon and overcoming resistance to anti-angiogenic therapy